Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff

-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant --

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on December 5, 2022, Spectrum's Board of Directors granted an aggregate of 736,988 inducement restricted stock units ("RSUs") to commercial non-executive employees who were hired specifically for the launch of ROLVEDON. The awards were granted under Spectrum's 2022 Employment Inducement Incentive Award Plan ("Inducement Plan") as employment inducement awards pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spectrum, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Spectrum, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over three years on the first three anniversaries of the grant date, subject to continued service through each applicable vesting date.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a pipeline with novel assets that serve areas of unmet need. For additional information on Spectrum please visit www.sppirx.com .

Notice Regarding Forward-looking statements

This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum's business and its future, including Spectrum's ability to successfully execute across the biopharmaceutical business model, including successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum's existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, the possibility that our commercialization efforts may not be successful, our dependence on third parties for manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™ and ROLVEDON™ are the Spectrum Pharmaceuticals' logos and trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 202   2 Spectrum Pharmaceuticals, Inc. All Rights Reserved

Tom Riga
Chief Executive Officer
949.788.6700
InvestorRelations@sppirx.com

Lisa Wilson
In-Site Communications, Inc.
212.452.2793
lwilson@insitecony.com

News Provided by Business Wire via QuoteMedia

NTR:CA,NTR
The Conversation (0)

Nutrien Announces Ken Seitz and Jeff Tarsi as Speakers at the BofA Investor Conference

Nutrien Ltd. (TSX and NYSE: NTR) announced today that Mr. Ken Seitz, Nutrien's President and Chief Executive Officer, and Mr. Jeff Tarsi, Nutrien's Executive Vice President and President, Global Retail, will be speaking at the 2025 BofA Global Agriculture and Materials Conference on Wednesday, February 26 at 10:30am EST.

The fireside chat will be video cast and available on the Company's website at https://www.nutrien.com/investors/events

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Combine harvester harvests ripe wheat.

Top 10 Phosphate Countries by Production

Phosphate is mainly used in the form of fertilizer for crops and animal feed supplements. Only 5 percent of world phosphate production is used for other applications, such as corrosion prevention and detergents.

Demand for phosphate fertilizers had created a US$54.6 billion market by 2023, and that figure is expected to grow at a compound annual growth rate of 5.3 percent through 2030 to reach US$78.4 billion.

"One of the primary factors influencing the worldwide market for phosphate fertilizers is the increasing focus on sustainable agriculture," according to Persistence Market Research. "Phosphate fertilizers, which are widely recognized for their ability to augment soil fertility and enhance crop productivity, are crucial for the pursuit of sustainability objectives in the agricultural industry."

Keep reading...Show less
Tractor on farm field.

9 Phosphate Stocks to Watch

Demand for both phosphate and potash fertilizers is anticipated to continue growing as the world’s population increases and the amount of arable land decreases.

The phosphate market is expected to witness a compound annual growth rate of 5.3 percent between 2023 and 2030 to reach US$78.4 billion. Driving this growth will be increasing pressure on global food supply brought on by rising populations and climate change, as well as inflation and downstream costs. Phosphate is also increasingly becoming a sought-after battery material for the electric vehicle industry due to its use in lithium-iron-phosphate (LFP) batteries.

Thankfully, phosphate-mining production around the globe is expected to increase, with the largest areas of growth being Africa and the Middle East. Phosphate mining companies with project developments in Brazil, Kazakhstan, Mexico, Peru and Russia are all expected to contribute to increased phosphate rock production as well.

Keep reading...Show less
Hands holding coins with a sprout growing out of them.

How to Invest in Phosphate (Updated 2024)

Discovering ways to invest in phosphate begins with understanding its primary uses.

Notably, about 90 percent of phosphate is consumed by the agriculture sector. Because of its essential properties, and since there is no known substitute for it, phosphate can be found in fertilizer products all over the world as a way to aid plant growth. It is also used as a supplement in animal feed, as a food preservative and for several other chemical purposes.

As the world's population grows and demand for food increases, the need for phosphate fertilizer is only expected to increase. For that reason, some believe phosphate investing is compelling. Read on for a brief overview of the phosphate market, including supply and demand dynamics and investing options.

Keep reading...Show less
farm crops in a field

5 Top Weekly TSXV Stocks: Arianne Phosphate Grows with Nearly 80 Percent Gain

The S&P/TSX Venture Composite Index (INDEXTSI:JX) dropped 1.1 points this past week to close at 551.23.

The Bank of Canada held steady, announcing on Wednesday (January 24) that it will be maintaining a 5 percent target for its key overnight rate. It based its decision on year-end inflation figures that peg inflation at 3.4 percent for December.

The central bank expects inflation to remain in the 3 percent range for the first six months of 2024, before easing toward its 2 percent target in 2025. Meanwhile, the Bank of Canada projects that the country's gross domestic product (GDP) will remain relatively flat in 2024; it is projecting a 0.8 percent increase for the year, with a 2.4 percent increase in 2025.

Keep reading...Show less
vegetable plantation

Understanding Raw Rock Phosphate: What Investors Need to Know

Phosphate is an essential component in global food production, with nearly 90 percent of all production going to the agriculture sector.

In addition to being a core ingredient in much of the world's fertilizer, the mineral is also used as a food preservative, to supplement animal feed and in products such as lithium iron phosphate batteries.

As the world's population continues to grow, demand for phosphate will only increase. While this trend can make phosphate a very attractive investment, it is not something one should dive into without research.

Keep reading...Show less

Latest Press Releases

Related News

×